Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dipartimento Materno-Infantile, Università degli Studi di Milano, Milano, Italy.
Int J Gynecol Cancer. 2013 Feb;23(2):244-8. doi: 10.1097/IGC.0b013e31827aa0bb.
This study aimed to analyze long-term survival of clear cells (CCs) and endometrioid (E) ovarian cancer cases according to presence of endometriosis in the pathologic report.
This is a retrospective analysis of 47 CC and 66 E ovarian cancer cases observed consecutively at our center between 1990 and 2010.All cases had first surgery at our center or were referred to it for treatment and follow-up.Cases were identified according to the original diagnosis reported in clinical records.All pathologic reports were reviewed, and cases were classified with or without pathologic evidence of endometriosis on the basis of the pathologic report.Follow-up was updated in March 2011. The follow-up median was 147 months (range, 116-171).
Endometriosis-associated ovarian cancer cases were more frequently diagnosed at stage I to II than cases without endometriosis: among the 36 endometriosis-associated ovarian cancer cases, 25 (69%) were at stage I or II, and the corresponding value was 35 (46%) of 77 among cases without endometriosis (P = 0.0173).The presence of endometriosis tended to be associated with a higher 10-year survival rate: after taking the potential confounding effect of stage into account, the finding was not statistically significant (hazards ratio, 0.7; 95% confidence interval, 0.3-1.5).
This analysis shows that EA CCs and E ovarian cases are diagnosed at an earlier stage than cases without endometriosis. No clear association emerged between presence of endometriosis and survival.
本研究旨在根据病理报告中是否存在子宫内膜异位症来分析透明细胞(CC)和子宫内膜样(E)卵巢癌病例的长期生存情况。
这是对 1990 年至 2010 年期间在我们中心连续观察的 47 例 CC 和 66 例 E 卵巢癌病例的回顾性分析。所有病例均在我们中心首次手术,或因治疗和随访而转诊至我们中心。根据临床记录中报告的原始诊断来识别病例。所有病理报告均经审查,并根据病理报告有无病理证据的子宫内膜异位症对病例进行分类。随访更新于 2011 年 3 月。随访中位数为 147 个月(范围,116-171)。
与无子宫内膜异位症的病例相比,伴有子宫内膜异位症的卵巢癌病例更常被诊断为 I 期至 II 期:在 36 例伴有子宫内膜异位症的卵巢癌病例中,25 例(69%)为 I 期或 II 期,而在 77 例无子宫内膜异位症的病例中,这一比例为 35 例(46%)(P=0.0173)。存在子宫内膜异位症倾向于与更高的 10 年生存率相关:在考虑到分期的潜在混杂效应后,这一发现没有统计学意义(风险比,0.7;95%置信区间,0.3-1.5)。
本分析表明,EA CC 和 E 卵巢癌病例的诊断分期早于无子宫内膜异位症的病例。子宫内膜异位症的存在与生存之间没有明显的关联。